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Previewseffective exercise is in reversing perturbed
insulin sensitivity and oxidative capacity
and (2) that because exercise activates
Ca2+, AMPK, SIRT1, and PGC1-a, the
possibility of targeting the adiponectin/
adipoR1pathway as a therapeutic is tangi-
ble. It must be emphasized, however, that
discovering any single pharmacological
agent that will mimic the broad range of
exercise-related health benefits is indeed
remote, and, alas, we should not put our
joggers into mothballs just yet! However,
identifying and targeting specific common
biochemical andmolecular componentsof
the exercise response are likely to lead to
viable drug therapies and prove beneficial
in the battle against such pathophysiol-
ogies as mitochondrial dysfunction in
obesity and insulin resistance.ACKNOWLEDGMENTS
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Dysregulation of autophagy contributes to aging and to diseases such as neurodegeneration, cardiomyop-
athy, and cancer. The paper by Yang et al. (2010) in this issue of Cell Metabolism indicates that defective au-
tophagymay also underlie impaired insulin sensitivity in obesity and that upregulating autophagy can combat
insulin resistance.Autophagy is responsible for the turnover
of long-lived proteins and of intracellular
structures that are damaged or function-
ally redundant. The process is essential
for the maintenance of cellular homeo-
stasis and is activated by starvation
(to supplyATP-producingsubstrates, e.g.,
amino acids) and other stress-inducing
conditions. Its dysregulation is involved
in many disorders and in aging (Meijer
and Codogno, 2009). In this issue of
Cell Metabolism, Yang et al. (2010) now
show that hepatic autophagy is defective
in obesity and diabetes and that its upre-
gulation improves insulin sensitivity.
During autophagy, part of the cytoplasm
is surrounded by a double membrane,presumably formed from the endoplasmic
reticulum (ER), to form an autophagosome
that then fuseswith lysosomes,afterwhich
the sequesteredmaterial is degraded. This
process requires the participation of au-
tophagy-related (ATG) proteins (seeMeijer
and Codogno, 2009 for review).
Autophagy is inhibited by the insulin-
amino acid-mTOR signaling pathway
via both short-term and long-term regula-
tion mechanisms. Short-term inhibition
canbeproducedby themammalian target
of rapamycin (mTOR) complex 1, which
causes phosphorylation and the inhibition
of ULK1 (the human homolog of yeast
ATG1). Long-term regulation occurs via
the transcription factors FoxO1 andFoxO3 (Liu et al., 2009), which control
the transcription of atg genes and become
phosphorylated and inhibited by insulin-
induced activation of protein kinase B
(Figure 1).
Recent evidence indicates that dysre-
gulation of autophagy is implicated in
obesity (characterized by ER stress,
insulin resistance, and glucose intoler-
ance; Hotamisligil, 2010) and in diabetes.
Mice fed a high-fat diet (HFD) have re-
duced hepatic autophagy (Liu et al.,
2009). However, autophagy, which is
essential for maintaining the structure
and function of b cells, is increased in
b cells during this period of HF feeding
(Ebato et al., 2008). In contrast, the11, June 9, 2010 ª2010 Elsevier Inc. 449














Figure 1. Autophagy and Insulin Resistance
Autophagy is controlled by insulin-amino acid-mTOR signaling. Overfeeding causes chronic ER stress,
which results in the downregulation of several of the proteins required for autophagy. This reinforces
ER stress and leads to insulin resistance. Overactivation of mTOR complex 1 (mTORC1) activates lipogen-
esis and thus contributes to obesity.
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Previewsdestruction of insulin production in b cells
by streptozotocin (STZ) increases au-
tophagy in the liver (Liu et al., 2009). Like-
wise, autophagy is also increased in
b cells derived from human subjects with
type-2 diabetes (Masini et al., 2009).
Yang et al. (2010) demonstrate that, not
only is hepatic autophagy severely de-
pressed in dietary (HFD for 16–22 weeks)
and genetic (ob/ob, db/db) models of
murine obesity and diabetes (as indicated
by the severe downregulation [>90%] of
the ATG proteins LC3, BECLIN1, ATG5,
and ATG7), but also that this process
may underlie the impaired insulin sensi-
tivity in these models. Thus, the suppres-
sion of hepatic ATG7 using shRNAi (using
an adenovirus-mediated approach) in
lean control mice resulted in insulin resis-
tance and ER stress. Similarly, suppres-
sion of ATG7 or ATG5 in in vitro cell
models caused defective insulin sign-
aling. Conversely, restoration of hepatic
autophagy in HFD-fed or in ob/ob mice,
by means of adenovirus-directed overex-
pression of ATG7, diminished ER stress,
counteracted insulin resistance, im-
proved hepatic fat metabolism, de-
creased gluconeogenesis, and increased
peripheral glucose disposal, effects that
could all be blunted by the expression of450 Cell Metabolism 11, June 9, 2010 ª2010dominant-negative ATG5. The latter
observation makes it unlikely that the
effect of ATG7 overexpression on insulin
sensitivity can be ascribed to some
unknown function of ATG7 that is unre-
lated to autophagy. Assuming that food
intake had remained unchanged under
these conditions, these data clearly
demonstrate that defective autophagy
and insulin resistance are closely linked.
At first sight, it is surprising that autoph-
agy can be restored by increasing the
expression of ATG7 alone, amidst many
other severely depressed ATG proteins.
Surprisingly, the expressionofATG7alone
also appeared to enhance the expression
of BECLIN 1, ATG 5, ATG12, and LC3
protein. The inhibition of calpain 2 at least
partially restored ATG7 levels, suggesting
that this Ca2+-dependent protease is
responsible for the decrease in ATG7
protein and other ATG proteins in the liver
of ob/obmice. The intimatemechanism of
this effect remains to be explored.
In order to rule out the possibility that
the chronic high insulin levels in ob/ob
mice were responsible for the reduced
levels of ATG proteins, STZ was adminis-
tered to the animals but did not restore the
hepatic levels of ATGs (in contrast to what
happened in lean mice, in which STZElsevier Inc.increased hepatic autophagy (Liu et al.,
2009; see above). Likewise, hepatic levels
of ATGs in db/db mice, in which insulin
levels were already very low, were also
severely depressed. These findings indi-
cate that it is the chronic obesity-related
ER stress rather than the high insulin
levels that is responsible for the low levels
of ATGs in the livers of these mice. An
additional contributing factor is that, in
obesity, mTOR in the liver is overacti-
vated, presumably as the result of
increased amino acid concentrations
(Newgard et al., 2009). This activates lipo-
genesis and decreases fatty acid oxida-
tion (Li et al., 2010), which exacerbates
the negative effects of the high fat content
of the diet.
Insulin inhibits autophagy, so one
would expect insulin resistance to disin-
hibit autophagy in order to protect cells
against oxidative stress (Meijer and Co-
dogno, 2009). In the case of b cells, au-
tophagy does indeed increase during the
initial period of HFD feeding, presumably
in order to protect the b cells and allow
them to boost their insulin production in
order to deal with the increased plasma
glucose concentrations. In contrast,
hepatic autophagy declines in obesity.
However, it may be that during the first
few weeks of HFD feeding, autophagy
increases before it starts to decline as
a result of continued stress. In the study
by Yang et al. (2010), autophagy was
unchanged after 7 weeks of HFD feeding
but declined thereafter; earlier time points
were not analyzed.
One may conclude that simply
increasing autophagy, e.g., by pharmaco-
logical means, would be sufficient to
improve insulin sensitivity in obesity.
Unfortunately, metabolism is more
complicated because autophagy is also
required for adipocyte differentiation; it is
the inhibition, rather than the stimulation,
of autophagy in adipocytes that gives
them a brown-fat-cell-like appearance
that favors fatty acid oxidation and
increases insulin sensitivity (Zhang et al.,
2009; Singh et al., 2009).
Yang et al. (2010) stress the many
parallels between pathologies associated
with obesity and the age-related impair-
ment of metabolism. During aging, au-
tophagy declines, and insulin resistance
can develop (Meijer and Codogno,
2009). The best way to increase autoph-
agy in vivo is by restricting calorie intake.
Cell Metabolism
PreviewsThough it has been known for decades
that calorie restriction is an effective way
to combat obesity-related insulin resis-
tance (and also aging), the present study
reveals a mechanism for these effects.
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Genome-wide association studies (GWAS) have been applied to complex diseases such as diabetes and
hypertension, successfully uncovering strong gene associations of potential pathophysiologic significance.
Recently, two studies (Ko¨ttgen et al., 2010; Chambers et al., 2010) have been applied to uncover genes
relevant to the pathophysiology of chronic kidney disease (CKD).Chronic kidney disease (CKD) is defined
as an irreversible reduction in glomerular
filtration rate (GFR), the first process of
urine production that often progresses to
end stage renal disease (ESRD), whereby
the level of GFR falls below the minimal
level to sustain life. The final common
pathway to ESRD, achieved regardless
of the initiating event, is characterized by
glomerular sclerosis, interstitial fibrosis,
and inflammation and loss of kidney func-
tion. The burden of ESRD worldwide is
growing, and as much as 13% of the
United States population is at risk (Coresh
et al., 2007). Animal studies have focused
on the profibrotic and inflammatory roles
of the renin-angiotensin system (RAS)
(Chevalier et al., 2009), and inhibition of
this system is the focus of current therapy.
This approach has proven only partially
successful, as such treatment delays
rather than prevents ESRD. Thus, theneed to identify better targets to prevent
ESRD is urgently needed. Genome-wide
association studies (GWAS) have been
widely used since 2005 (Klein et al.,
2005) to understand the underlying ge-
netic component(s) of complex pheno-
types, i.e., phenotypes that do not exhibit
classical Mendelian inheritance resulting
from a single gene alteration (Lander
and Schork, 1994). More than any other
approach, these studies have reproduc-
ibly associated closely linked genetic
loci, identified by single nucleotide poly-
morphisms (SNPs), to these traits. At
best, they have led to the delineation in
many parts of the human genome of
sequences showing association with
common disease traits, e.g., diabetes,
obesity, hypertension, etc. and have also
been used to find association with normal
physical traits such as height, hair, and
eye color (Hindorff et al., 2010). GWASrequire the study of the DNA from several
thousands of individuals with and without
a demonstrable and measurable pheno-
type. SNPs associated with these charac-
teristics are identified by hybridization
with known SNP arrays. An international
project has developed a haplotype map
(HapMap; http://hapmap.ncbi.nlm.nih.
gov/) of the genome, which identifies
variable regions of the human genome
and associated genetic variation. Once
the associated areas of DNA have been
located, there follows a search in the
region to find candidate genes potentially
involved in the pathologic physiology
responsible for susceptibility to the trait
or disease under investigation. In most
GWAS, each discovered DNA variant
usually has only a small impact on the
increased risk of the disease, as was pre-
dicted 50 years ago by D.S. Falconer
(1960), and that is also the case in two11, June 9, 2010 ª2010 Elsevier Inc. 451
